Latest news:

  • December 2019
    • Pre Diagnostics presents two posters at the Clinicalt Trial in Alzheimers Disease congress in San Diego
      • Assessing Aβ clearance aided by mass spectrometry
      • A new blood-based biomarker of Aβ clearance – The monocyte Aβ mid-domain assay

About Pre Diagnostics AS

Pre Diagnostics is an innovative Norwegian diagnostic company that seeks to create value for patients, partners, and investors by developing pioneering and patient-friendly, in-vitro diagnostic (IVD) products for early detection of diseases.

The company’s proprietary concept is built upon the scientific premise that a disease evokes systemic responses in macrophages unique to that disease which can be accurately measured in the blood samples of patients.

Pre Diagnostics aims to be a leader in the diagnosis of early Alzheimer’s disease and is thus focused on the development of IVD biomarker products that use well-established technologies and procedures.

The company protects its technology with an evolving patent portfolio.